Scientific Reports (Nov 2022)

Serological fingerprints link antiviral activity of therapeutic antibodies to affinity and concentration

  • Sebastian Fiedler,
  • Sean R. A. Devenish,
  • Alexey S. Morgunov,
  • Alison Ilsley,
  • Francesco Ricci,
  • Marc Emmenegger,
  • Vasilis Kosmoliaptsis,
  • Elitza S. Theel,
  • John R. Mills,
  • Anton M. Sholukh,
  • Adriano Aguzzi,
  • Akiko Iwasaki,
  • Andrew K. Lynn,
  • Tuomas P. J. Knowles

DOI
https://doi.org/10.1038/s41598-022-22214-z
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 10

Abstract

Read online

Abstract The effectiveness of therapeutic monoclonal antibodies (mAbs) against variants of the SARS-CoV-2 virus is highly variable. As target recognition of mAbs relies on tight binding affinity, we assessed the affinities of five therapeutic mAbs to the receptor binding domain (RBD) of wild type (A), Delta (B.1.617.2), and Omicron BA.1 SARS-CoV-2 (B.1.1.529.1) spike using microfluidic diffusional sizing (MDS). Four therapeutic mAbs showed strongly reduced affinity to Omicron BA.1 RBD, whereas one (sotrovimab) was less impacted. These affinity reductions correlate with reduced antiviral activities suggesting that affinity could serve as a rapid indicator for activity before time-consuming virus neutralization assays are performed. We also compared the same mAbs to serological fingerprints (affinity and concentration) obtained by MDS of antibodies in sera of 65 convalescent individuals. The affinities of the therapeutic mAbs to wild type and Delta RBD were similar to the serum antibody response, indicating high antiviral activities. For Omicron BA.1 RBD, only sotrovimab retained affinities within the range of the serum antibody response, in agreement with high antiviral activity. These results suggest that serological fingerprints provide a route to evaluating affinity and antiviral activity of mAb drugs and could guide the development of new therapeutics.